During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
CASE SUMMARY
A woman aged 72 years and never smoker presented to her primary care physician with a persistent, nonproductive cough; loss of appetite; and she experienced pruritus for 4 months. Her contrast-enhanced chest/abdomen/pelvis CT scan showed a 4.1×3.8-cm tumor in the left upper lobe with calcification and left hilar lymphadenopathy, but an MRI scan of her brain was negative for any intracranial activity. After the patient underwent a transbronchial biopsy, her immunohistochemistry panel came back negative for ALK and TPK1 mutations but was positive for TTF1. An antibody assay came back with a PD-L1 measurement of 25%. Her concurrent tissue- and plasma-based next-generation sequencing (NGS) panel was positive for an EGFR exon 21 L858R mutation and she was diagnosed with stage IV adenocarcinoma.
DISCUSSION QUESTIONS
JOSHUA SABARI, MD: [We use NGS] upfront; that's the key here. Historically, we were testing at [the time of] progression only and starting chemotherapy, but ever since the advent of immunotherapy and since it's entered the frontline, we need to test [for mutations] upfront. We can't wait [to test] patients when they’re in the second-line setting, and we know there are survival benefits for a lot of these targeted therapies in the frontline setting.
In this case, with a [patient who has a] PD-L1 expression of 25% and is a never smoker, if you don't have the results of the NGS testing back yet would anyone consider starting immunotherapy or chemoimmunotherapy? No, there would be no takers [in that situation], because everybody is going to wait for the NGS results and start the best possible therapy, and we certainly don't want to give the patient the wrong therapy. A lot of times, patients only have 1 potential line of therapy, and they don't have the ability to get further lines of therapy. We never know if someone's going to make it to the second line, so we want to use our best therapies first.
What if the patient had a PD-L1 expression of 100%? Would that change anyone's opinion [regarding their approach to treating the patient]?
JOSHUA STRAUSS, MD: No, I don't pay attention to the PD-L1 status in [patients positive for an] EGFR mutation.
SABARI: I agree. There’re many prospective trials [for these patients], such as including chemotherapy and immunotherapy after [the use of osimertinib (Tagrisso)], and unfortunately there's been no significant benefits in the EGFR-mutant patient population. So there's very little role for immunotherapy here, with the one caveat being the IMpower150 study [NCT02366143], which is the use of carboplatin, paclitaxel, and atezolizumab [Tecentriq] plus bevacizumab [Avastin].1 There are also data for patients post-disease progression on osimertinib that showed a potential benefit for the EGFR- and ALK-positive patient populations, but it's not a commonly-used regimen here in the United States. In China it's a commonly used regimen in the second-line setting.2
Does the presence of an EGFR L858R mutation vs an exon 19 deletion change anybody's approach as well?
BRUCE KAPPEL, MD: I don't get into that unless we get into the bizarre [mutations that require a very different approach].
AQEEL GILLANI, MD: I'm with Dr Kappel on that one. I don't think we get into the weeds [when we see these mutations]. I see exon 19 deletion and L858R EGFR mutations as identical. Some differences, but [not many].
NGS and ctDNA Considered in Advanced Breast Cancer After Progression
May 3rd 2024During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Read More
Tolerability Helps Decide Third-Line Treatment in Advanced RCC
April 30th 2024During a Case-Based Roundtable® Chandler H. Park, MD, led a discussion on the considerations physicians have when deciding on their treatment approach in the third line for patients with advanced renal cell carcinoma in the first article of a 2-part series.
Read More
Intracranial Response Data Supports Use of Brigatinib in ALK+ NSCLC
April 26th 2024During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed the intracranial efficacy of brigatinib from the ALTA-1L trial for patients with ALK+ non–small cell lung cancer in the first article of a 2-part series.
Read More
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More